Independent pharmacies are entering 2026 in an environment defined by heightened oversight, stricter pharmacy benefit manager (PBM) audit practices, and more aggressive contractual enforcement. While scrutiny of the PBM industry itself continues at both the federal and state levels, PBMs are simultaneously tightening control over their networks, making it critical for independents to understand how these developments will affect operations, reimbursement, and long-term viability. For many pharmacies, staying ahead of PBM enforcement trends will be the difference between stability and sudden disruption.

What PBM Oversight Means for Independents in 2026

The growing wave of federal inquiries from agencies such as the Federal Trade Commission (FTC) and Centers for Medicare & Medicaid Services (CMS) has led PBMs to recalibrate internal protocols and shift risk downstream to providers. As PBMs overhaul audit strategies and reimbursement methodologies in response to regulatory pressure, independents are seeing an increase in point-of-sale discrepancies, retroactive clawbacks, and expanded documentation demands. These enforcement changes are not theoretical; they are already shaping PBM behavior and will intensify throughout 2026.

DIR Reform and the Emergence of New Audit Triggers

One of the most significant shifts involves the continued impact of CMS’s overhaul of DIR fees, requiring that nearly all price concessions be included at the point of sale. This change, while intended to bring transparency to patient pricing, has led PBMs to develop new audit triggers and reimbursement models to recover revenue they previously captured through retroactive fees. Indeed, PBMs already  look for any variance and/or discrepancy that can justify repayment demands. This trend is expected to accelerate as PBMs refine data analytics tools that identify prescriber patterns, patient utilization anomalies, and high-cost drug activity.

Rising Audit Frequency and Documentation Demands

Independent pharmacies, especially those dispensing specialty, chronic disease, or high-cost medications, should anticipate more frequent PBM audits as well as regular requests for claims validation, prescriber authorization records, and drug acquisition proof.

PBM Audits Are Becoming More Aggressive and Expansive

Indeed, PBM audits themselves are becoming broader, deeper, and more adversarial. Independents are encountering expanded audits that examine not only traditional documentation but also inventory controls, supplier relationships, and prior authorization workflows. Seemingly minor clerical errors and/or isolated inventory differences are increasingly characterized as “patterns” of non-compliance, forming the basis for recoupments or PBM network terminations. The rise in cross-network enforcement, where PBMs remove multiple pharmacies allegedly linked through common ownership, will create additional exposure for independents with multiple pharmacies.

Government Enforcement Risk Is Increasing

False Claims Act theories and government investigations will intersect with PBM findings more than ever. PBM audit results can be shared with plans, state agencies, or federal authorities, transforming contract disputes into allegations of fraudulent billing or improper dispensing. For independents, this means that even routine PBM discrepancies may create risk far beyond reimbursement issues. Pharmacies must ensure that clinical documentation, dispensing workflows, and billing systems are aligned not only with PBM manuals but also with broader healthcare compliance standards.

How Pharmacies Can Prepare for 2026’s PBM Enforcement Climate

Going into 2026, independent pharmacies should prioritize proactive compliance, meticulous documentation, and rapid response strategies. This includes regular internal reviews of PBM provider manuals, updating operating procedures, enhancing inventory management systems and protocols, and maintaining clear clinical rationales for high-cost therapies. Pharmacies that invest in preventative measures are far better positioned to reduce audit exposure, contest improper determinations, and avoid sudden termination from essential networks.

HLA’s PBM legal team supports independent pharmacies nationwide in navigating this increasingly complex PBM environment. We help providers prepare for and respond to PBM audits, challenge improper network terminations, develop compliance frameworks, and protect pharmacies from escalating enforcement pressures. As PBM enforcement trends for 2026 continue to evolve, independent pharmacies that partner with experienced healthcare counsel will be equipped to safeguard their reimbursements, preserve patient access, and maintain operational stability in the face of unprecedented scrutiny.

How HLA Can Help

If your pharmacy is facing a PBM audit, network termination threat, or needs guidance to prepare for 2026’s intensified enforcement climate, we are here to help. Contact us today for a free legal consultation.

‍